Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic
Open Access
Abstract
Background: The global COVID-19 pandemic has resulted in approximately 7 million deaths and a historic vaccination effort, with over 13.6 billion doses administered. Despite this, understanding of immune responses in vulnerable populations, such as transplant recipients (TR) and hemodialysis patients (HD), remains limited, especially outside the US and Europe. Methods: To address this gap, we analyzed blood samples and deidentified data from the Instituto Nacional de Coordinación de Trasplante (INCORT) in The Dominican Republic, measuring antibody levels to SARS-CoV-2 post-infection and vaccination with BNT162b2 (Pfizer-BioNTech) and Sinovac-CoronaVac (Sinovac) in TR, HD, and healthy controls (CO). Using a fluorescent multiplex assay (mPlex-CoV) and mixed-effects modeling, we assessed variations in anti-S, anti-RBD, and anti-N IgG antibodies. Results: The results indicate that the CO group experienced an early peak in anti-S and anti-RBD antibodies, followed by stabilization. In contrast, the TR and HD groups showed a slower, gradual increase in antibodies. Despite fluctuations in the HD group, both the TR and HD groups maintained high anti-S and anti-RBD IgG levels, indicating a back-boosting effect from vaccination. However, elevated anti-N IgG levels in the TR and HD groups suggest potential reinfections. Additionally, prior SARS-CoV-2 infection led to higher anti-S IgG levels, with BNT162b2 associated with higher anti-S IgG and CoronaVac associated with higher anti-N IgG levels. Conclusion: These findings highlight the variability in antibody responses and the need for targeted public health strategies to diverse immunological profiles.Keywords
Funding Information
- National Center for Advancing Translational Sciences of the National Institutes of Health (UL1 TR002001, TL1 TR002000)
This publication has 43 references indexed in Scilit:
- Incident COVID-19 and Hospitalizations by Variant Era Among Vaccinated Solid Organ Transplant RecipientsJAMA Network Open, 2023
- Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccineThe Lancet Regional Health - Europe, 2021
- Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKDKidney International Reports, 2021
- Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysisKidney International, 2021
- Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following InfectionJournal of General Internal Medicine, 2021
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 DosesJAMA, 2021
- Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individualsInternational Journal of Infectious Diseases, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2Clinics In Laboratory Medicine, 2020